S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   162.99 (+1.72%)
MSFT   336.11 (-0.15%)
FB   335.49 (-0.75%)
GOOGL   2,918.37 (+0.27%)
AMZN   3,578.49 (+0.48%)
TSLA   1,163.12 (+2.30%)
NVDA   331.68 (-0.62%)
BABA   129.97 (-1.25%)
NIO   41.05 (+1.46%)
CGC   10.92 (-1.27%)
AMD   163.54 (+1.01%)
GE   96.45 (-1.98%)
MU   86.33 (+0.22%)
T   23.19 (-2.93%)
F   19.56 (-0.56%)
DIS   146.40 (-0.95%)
ACB   6.44 (+0.00%)
AMC   35.70 (-3.09%)
PFE   53.19 (+1.51%)
BA   196.31 (-1.10%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   162.99 (+1.72%)
MSFT   336.11 (-0.15%)
FB   335.49 (-0.75%)
GOOGL   2,918.37 (+0.27%)
AMZN   3,578.49 (+0.48%)
TSLA   1,163.12 (+2.30%)
NVDA   331.68 (-0.62%)
BABA   129.97 (-1.25%)
NIO   41.05 (+1.46%)
CGC   10.92 (-1.27%)
AMD   163.54 (+1.01%)
GE   96.45 (-1.98%)
MU   86.33 (+0.22%)
T   23.19 (-2.93%)
F   19.56 (-0.56%)
DIS   146.40 (-0.95%)
ACB   6.44 (+0.00%)
AMC   35.70 (-3.09%)
PFE   53.19 (+1.51%)
BA   196.31 (-1.10%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   162.99 (+1.72%)
MSFT   336.11 (-0.15%)
FB   335.49 (-0.75%)
GOOGL   2,918.37 (+0.27%)
AMZN   3,578.49 (+0.48%)
TSLA   1,163.12 (+2.30%)
NVDA   331.68 (-0.62%)
BABA   129.97 (-1.25%)
NIO   41.05 (+1.46%)
CGC   10.92 (-1.27%)
AMD   163.54 (+1.01%)
GE   96.45 (-1.98%)
MU   86.33 (+0.22%)
T   23.19 (-2.93%)
F   19.56 (-0.56%)
DIS   146.40 (-0.95%)
ACB   6.44 (+0.00%)
AMC   35.70 (-3.09%)
PFE   53.19 (+1.51%)
BA   196.31 (-1.10%)
S&P 500   4,632.40 (-0.49%)
DOW   34,858.42 (-0.79%)
QQQ   400.33 (+0.16%)
AAPL   162.99 (+1.72%)
MSFT   336.11 (-0.15%)
FB   335.49 (-0.75%)
GOOGL   2,918.37 (+0.27%)
AMZN   3,578.49 (+0.48%)
TSLA   1,163.12 (+2.30%)
NVDA   331.68 (-0.62%)
BABA   129.97 (-1.25%)
NIO   41.05 (+1.46%)
CGC   10.92 (-1.27%)
AMD   163.54 (+1.01%)
GE   96.45 (-1.98%)
MU   86.33 (+0.22%)
T   23.19 (-2.93%)
F   19.56 (-0.56%)
DIS   146.40 (-0.95%)
ACB   6.44 (+0.00%)
AMC   35.70 (-3.09%)
PFE   53.19 (+1.51%)
BA   196.31 (-1.10%)
NASDAQ:EXAI

Exscientia News Headlines

$21.34
-0.55 (-2.51%)
(As of 11/30/2021 09:58 AM ET)
Add
Compare
Today's Range
$21.34
$21.44
50-Day Range
N/A
52-Week Range
$19.03
$30.38
Volume
90 shs
Average Volume
59,712 shs
Market Capitalization
$2.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Media Mentions By Week



Exscientia Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

EXAI
News Sentiment

0.00

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

EXAI Articles
This Week

0

1

EXAI Articles
Average Week

Get Exscientia News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.

Exscientia (NASDAQ:EXAI) News Headlines Today

SourceHeadline
finance.yahoo.com logoExscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
finance.yahoo.com - November 23 at 9:03 AM
benzinga.com logoExscientia Reports Q3 Sales £17.6M Up From £1.0M YoY
benzinga.com - November 17 at 6:50 PM
finance.yahoo.com logoExscientia Business Update for Third Quarter 2021
finance.yahoo.com - November 17 at 6:50 PM
MarketBeat logoExscientia (EXAI) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - November 12 at 9:34 AM
finance.yahoo.com logoExscientia to Report Third Quarter 2021 Financial Results on November 17, 2021
finance.yahoo.com - November 10 at 8:56 AM
nasdaq.com logoExscientia Plc American Depositary Shares (EXAI)
nasdaq.com - October 15 at 12:06 AM
finance.yahoo.com logoPublication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes
finance.yahoo.com - October 11 at 5:31 PM
finance.yahoo.com logoCiti Appointed as Depositary Bank for Exscientia plc’s ADR Programme
finance.yahoo.com - October 6 at 11:37 AM
businesswire.com logoExscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters’ Option to ...
businesswire.com - October 6 at 11:37 AM
finance.yahoo.com logoExscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters’ Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement
finance.yahoo.com - October 5 at 5:16 PM
finance.yahoo.com logoExscientia Announces Pricing of $304.7 Million Upsized Initial Public Offering and $160.0 Million Concurrent Private Placements
finance.yahoo.com - October 4 at 11:05 AM
Get Exscientia News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.